SA
SVA

SAIF Advisors’s Sinovac Biotech, Ltd SVA Stock Holding History

SAIF Advisors’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$405M Hold
10,780,820
– – 92.64% 1
2021
Q1 		$405M Hold
10,780,820
– – 85.85% 1
2020
Q4 		$69.8M Buy
+10,780,820
New +$69.8M 47.42% 1
2017
Q3 		$76M Hold
10,780,820
– – 100% 1
2017
Q2 		$72.8M Hold
10,780,820
– – 87.02% 1
2017
Q1 		$61.8M Hold
10,780,820
– – 87.08% 1
2016
Q4 		$63.6M Buy
+10,780,820
New +$64.8M 35.64% 2

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SAIF Advisors's SVA Position: Q2 2021 in Review

SAIF Advisors held its Sinovac Biotech, Ltd (SVA) position steady in Q2 2021 at 10,780,820 shares worth $405M. The position accounts for 92.64% of the portfolio, ranked #1.

SAIF Advisors first reported a position in SVA in Q4 2016 and has held it in 7 quarters since. 28 funds tracked by Wall St. Rank hold SVA as of Q2 2021.

  • SAIF Advisors held 10,780,820 shares of Sinovac Biotech, Ltd worth $405M as of Q2 2021.
  • SAIF Advisors left its Sinovac Biotech, Ltd share count unchanged in Q2 2021.
  • Sinovac Biotech, Ltd made up 92.64% of SAIF Advisors's portfolio in Q2 2021, its #1 holding.
  • SAIF Advisors first reported a position in Sinovac Biotech, Ltd in Q4 2016 and has held it in 7 quarters since.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2021.

Based on SAIF Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.